At least there's one thing good, they have not diluted any shares (assuming the numbers posted are correct). Since they appear to be restricted from doing anything it doesn't mean they don't want to dilute. It would be crazy to dilute at this pps but desperate times require desperate measures. As we approach 2022, it's hard to believe that in the beginning of 2021 things were looking very promising. What a turn of events! Who knows, maybe the the combination of the investigation(s) & the lack of funding has taken it's toll. When you add everything in it's totality, even giving up the office looks bad. Even if one thinks big pharmaceutical was holding us back I suppose it really doesn't matter. At the end of the day, this is in the tanker. It was a risk that appears to have failed.